CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing generics market
4.1.2. Rising adoption of orally disintegrating tablets
4.1.3. The emergence of new superdisintegrants for the pharmaceutical industry
4.2. Market Restraints & Challenges
4.2.1. Concerns regarding safety and quality
4.3. Market Opportunities
4.3.1. Pharmaceutical market expansion in emerging countries
CHAPTER 5. GLOBAL SUPERDISINTEGRANTS MARKET – BY TYPE
5.1. Synthetic Superdisintegrants
5.1.1. Crospovidone
5.1.2. Modified starch
5.1.3. Modified cellulose
5.1.4. Croscarmellose sodium
5.1.5. Low-substituted hydroxypropyl cellulose
5.1.6. Calcium silicates
5.1.7. Ion exchange resins
5.2. Natural Superdisintegrants
5.3. Other Superdisintegrants
CHAPTER 6. GLOBAL SUPERDISINTEGRANTS MARKET – BY FORMULATION
6.1. Capsules
6.2. Tablets
CHAPTER 7. GLOBAL SUPERDISINTEGRANTS MARKET – BY THERAPEUTIC
AREA
7.1. Neurological Diseases
7.2. Gastrointestinal Diseases
7.3. Oncology
7.4. Inflammatory Diseases
7.5. Infectious Diseases
7.6. Cardiovascular Diseases
7.7. Haematological Diseases
CHAPTER 8. GLOBAL SUPERDISINTEGRANTS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL SUPERDISINTEGRANTS MARKET - COMPANY
PROFILES
9.1. DFE Pharma
9.2. JRS Pharma LP
9.3. Asahi Kasei Corporation
9.4. Merck KGaA
9.5. Corel Pharma Chem
9.6. Avantor Performance Materials, LLC
9.7. BASF SE
9.8. Ashland, Inc.
9.9. The Dow Chemical Company
9.10. Roquette Freres
9.11. Nippon Soda Co., Ltd.
9.12. Huber Corporation
9.13. FMC Corporation
9.14. Millipore Sigma
CHAPTER 10. GLOBAL SUPERDISINTEGRANTS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
